The global hepatitis B treatment market is expected to register an approximate CAGR of 5.3% during the forecast period, i.e., from 2018 to 2024.
Hepatitis is a viral infection caused by Hepatitis A, B or C virus. The infection results to cause liver infection or inflammation and many times leading to liver damage.
Hepatitis B virus spreads through coming in contact with infected blood, drinking contaminated water, and using infected needles or syringes. The person suffering from Hepatitis B faces various symptoms such as poor appetite, weakness, jaundice, dark-colored urine, itching on skin, swelling on legs, weight loss, drowsiness and many more. According to the World Health Organization 2018 fact sheet, it was estimated that 257 million people across the world have lived with hepatitis B infection and also mentioned that around 887,000 number of people died from hepatitis B in 2015. Thus, the increasing prevalence of Hepatitis B across the world boosts market growth.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7817
However, the factors such as side effects associated with treatment and medications hinder the market growth.
Hepatitis B Treatment Market Segmentation
The global hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.
Based on type, the market is segmented into acute and chronic. On the basis of treatment, the global hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.
Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Hepatitis B Treatment Market Key players
Some of the key players in the global hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others.
Hepatitis B Treatment Regional Market Summary
Sources: Centers for Disease Control and Prevention, GOV.UK, Society of Cardiovascular Computed Tomography, Indian Brand Equity Foundation, Annual Reports, Press Release, White Paper, And Company Presentation
The Americas dominates the global market for hepatitis B treatment owing to the increasing bacterial infection, development in the clinical practices, and availability and access of best treatments for viral infection in this region.
Moreover, high healthcare expenditure within the Americas boosts the regional market. According to the National Vaccine Information Center, there were 3,370 acute cases of hepatitis B in the US in 2015. Following similar trends, Europe stood second in the global hepatitis B treatment market. On a regional basis, the European market is segmented into Western Europe and Eastern Europe. Europe is estimated to lead the market due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population. According to the World Health Organization data sheet, hepatitis B and C affects a large number of people in the European region. It also, stats that globally, 1.5 million people die every year because of hepatitis B virus. The increasing incidences of hepatitis B in Europe boost market growth.
Asia Pacific is estimated to be the fastest growing region for the global hepatitis B treatment market in 2017. A rapidly growing medical diagnostic sector, growing prevalence of bacterial infection and a large number of patients suffering from HIV infection support market growth.
On the other hand, the Middle East and Africa hold the least share in the global hepatitis B treatment market owing to stringent government policies, presence of poor economies, lack of awareness, and low healthcare expenditure within the region.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hepatitis-b-treatment-market-7817
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment